Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azithromycin for ocular toxoplasmosis

A Rothova1, L E Bosch-Driessen, N H van Loon

  • 1Department of Ophthalmology, FC Donders Institute, Academic Hospital Utrecht, Netherlands.

The British Journal of Ophthalmology
|January 30, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of conjunctival, episcleral and scleral thickness in healthy individuals using anterior segment optical coherence tomography.

Acta ophthalmologica·2023
Same author

Subconjunctival Rituximab Administration for the Treatment of Scleritis.

Ocular immunology and inflammation·2022
Same author

Clinical Relevance of Autoantibodies and Inflammatory Parameters in Non-infectious Scleritis.

Ocular immunology and inflammation·2021
Same author

Recurrences of Scleritis after Ocular Surgery.

Ocular immunology and inflammation·2021
Same author

Current insights in the pathogenesis of scleritis.

Experimental eye research·2020
Same author

Successful Tocilizumab Treatment for Scleritis.

Ocular immunology and inflammation·2019
Same journal

Novel technique for treating extraocular muscle adherence after fracture repair.

The British journal of ophthalmology·2026
Same journal

Safe use of fluorinated gases in vitreoretinal surgery: learning from patient safety incidents with expert panel recommendations from the British and Eire Association of Vitreoretinal Surgeons (BEAVRS).

The British journal of ophthalmology·2026
Same journal

Fast progressors in Asian normal-tension glaucoma: 10 years and beyond in a longitudinal cohort.

The British journal of ophthalmology·2026
Same journal

Identifying patients with poor visual outcomes after primary rhegmatogenous retinal detachment surgery using machine learning.

The British journal of ophthalmology·2026
Same journal

Incidence of bilateral disease and choroidal neovascularisation in punctate inner choroiditis.

The British journal of ophthalmology·2026
Same journal

Reference map of multimodal vision deficits in intermediate age-related macular degeneration: contrast sensitivity and low-contrast visual acuity.

The British journal of ophthalmology·2026
See all related articles

Azithromycin effectively reduced ocular inflammation in patients with ocular toxoplasmosis. While it did not prevent recurrence, it served as a well-tolerated alternative for those unable to use standard treatments.

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Pharmacology

Background:

  • Ocular toxoplasmosis is a parasitic infection causing inflammation in the eye.
  • Standard treatments like pyrimethamine and sulphadiazine can have significant side effects.

Purpose of the Study:

  • To evaluate the effectiveness of azithromycin in treating ocular toxoplasmosis.
  • To assess azithromycin as a potential alternative therapy.

Main Methods:

  • 11 immunocompetent patients with ocular toxoplasmosis received azithromycin.
  • Treatment involved a loading dose followed by daily administration for 5 weeks.
  • Patients underwent regular ocular and systemic examinations with a minimum 1-year follow-up.

Main Results:

Related Experiment Videos

  • Intraocular inflammation resolved within 4 weeks in 7 out of 11 patients.
  • Two patients with progressive retinitis showed improvement despite prior treatment failure.
  • Recurrence of retinitis occurred in 27% of patients within the first year.
  • No systemic side effects were reported with azithromycin use.

Conclusions:

  • Azithromycin demonstrates efficacy in resolving acute ocular inflammation associated with toxoplasmosis.
  • It is a viable, well-tolerated alternative for patients intolerant to conventional therapies.
  • Azithromycin does not appear to prevent disease recurrence.